Alza Corporation

Other

Janssen Pharmaceutica Nv

Patrick S-l Wong

David E Edgren

Vincent Joseph Ferrari

Nathan Roth

Liang-Chang Dong

Jeffrey Wayne Etter

Phyllis I Gardner

James Horvath

Felix T Theeuwes

Atul D Ayer

Gurdish K Bhatti

Francisco Jao

Shu W Li

Andrew I Poutiatine

Christopher M Ohms

Miriam A Martin

Howard B Rosen

Si-Hong Yum

Jason J Wan

Peter E Daddona

Liang C Dong

Joseph Creagan Trautman

George V Guittard

Michael A DesJardin

Brenda J Pollock

Hoa T Huynh

Frank Jao

Padmaja Shivanand

Pamela K Wat

Robert R Skluzacek

Crystal Pollock

Hyunok Lynn Kim

Kathy Mc Chesney

Michael G Zuck

Joyce C Anthony

Christopher M G Ohms

Stephen S Hwang

Yolanda M Puga

Richard L-c Yieh

Keru O Shafi

Ted Smith

Radomir N Vukadin

A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.

Extended release dosage form

A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.

System for delaying drug delivery up to seven hours

A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Pharmaceutical coating composition and method of use

An osmotic caplet is disclosed comprising an osmotic caplet exit for delivering a preselected dose of drug to a patient in need of therapy.

Osmotic caplet

A dosage form manufactured from an extruded polymer tube and method for manufacturing the dosage form are disclosed. The dosage form is preferably an osmotic dosage form and includes a therapeutic agent and an expandable composition contained within the lumen of the extruded polymer tube.

Osmotic dosage form composed of an extruded polymer tube form

The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of a liquid, active agent formulation to a fluid environment of use. The liquid, active agent formulation is sorbed into porous particles that are dispersed in a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix may be surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.

Gastric retaining oral liquid dosage form

The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.

Prolonged release active agent dosage form adapted for gastric retention

The present invention is directed to an active agent dosage form and methods of its fabrication which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface one or more insoluble bands located in complementary grooves. The invention is also directed to articles of manufacture, methods and systems for fabricating the active agent dosage form.

Method of fabricating a banded prolonged release active agent dosage form

The present invention is directed to an oral active agent delivery system and method for delivering discrete units of an active agent formulation to a patient. An active agent formulation chamber containing the active agent formulation and having a fluid passing active agent formulation retainer is placed at a first end into a fluid and at a second end into a patient's mouth. The active agent is delivered when the patient sips on the second end of the chamber.

Oral delivery of discrete units

A device (,) comprising a sheet member (,) having a plurality of microprotrusions (,) for penetrating the skin and a rigid support (,) contacting and extending across the sheet member (,) for transmitting an applied force evenly across the length and width of the sheet member (,) to reproducibly and reliably penetrate the skin with the microprotrusions (,).

Device for enhancing transdermal agent flux

The present invention is directed to an active agent dosage that is useful for the prolonged delivery of an active agent formulation to fluid environment of use. The active agent dosage form is a matrix that has an insoluble material circumscribing a portion of the surface of the matrix. The invention is also directed to a method of making the active agent dosage form.

Banded prolonged release active agent dosage form

This invention pertains to a dosage form for the management of epilepsies wherein the dosage form comprises administering valproic acid or a valproic acid derivative at a continuous rate over an extended time.

Method for providing sustained antiepileptic therapy

Oral active agent delivery system having improved flow controllers. A hollow tubular member containing the active agent formulation and having a fluid passing controller is placed at one end into a fluid and at a second end into a patient's mouth. The active agent is delivered when the patient sips on the end of the chamber. The improved controllers prevent leakage of the active agent formulation.

Flow controller configurations for an active agent delivery device

The present invention is an oral active agent delivery system and method for delivering discrete units of an active agent formulation to a patient. An active agent formulation chamber containing the active agent formulation and having a fluid passing active agent formulation retainer is placed at a first end into a fluid and at a second end into a patient's mouth. The active agent is delivered when the patient sips on the second end of the chamber.

Growing community of inventors

Palo Alto, CA, United States of America

Patrick S-l Wong